GlobeNewswire·Nov 9, 2026, 8:30 AM ET

Pliant Therapeutics Announces Presentation of PLN-101095 Preclinical and Clinical Data at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer

Pliant Therapeutics presented preclinical proof-of-concept data and new clinical biomarker analyses for PLN-101095 at the 41st Annual Meeting of the Society for Immunotherapy of Cancer on November 9, 2026.
Preclinical data showed that blocking integrins αvβ8 and αvβ1 combined with anti-PD-1 reduced TGF-β signaling, modulated fibroblastic cells, increased CD8+ T cell infiltration, and improved anti-tumor survival.
These findings support the ongoing Phase I clinical trial (NCT06270706) of PLN-101095 in combination with pembrolizumab for solid cancers.
Biomarker data from the Phase I trial indicated that early immune activation during PLN-101095 monotherapy predicts clinical response after initiating pembrolizumab combination therapy.
The FORTIFY Phase 1b trial is enrolling patients with non-small cell lung cancer, high tumor mutational burden tumors, or clear cell renal cell carcinoma.
Patients in the FORTIFY trial receive 1,000 mg of PLN-101095 twice daily for 14 days as monotherapy before adding pembrolizumab.
PLN-101095 is an oral, dual-selective inhibitor of αvβ8 and αvβ1 integrins developed for ICI-refractory advanced or metastatic solid tumors.
Pliant Therapeutics is also pursuing integrin-based drug delivery platforms to target siRNAs to skeletal muscle, adipocytes, and renal cells.